Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
Halifax, Nova Scotia – (Newsfile Corp. – May 15, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce the successful completion of bacterial endotoxin testing (“BET”) on Sona’s uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate (“LAL”) method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US.
